AIM: The coronavirus disease (COVID-19) pandemic has reportedly leaded to anxiety in women during pregnancy around the world. Anxiety during pregnancy is known to have negative outcomes for pregnancy and the baby. The aim of this study is to describe anxiety levels and behavioral changes of pregnant women during the COVID-19 pandemic at Fauziah Mother and Child Hospital Tulungagung, East Java. METHODS: This descriptive study involved 30 pregnant women. The instrument used was a questionnaire asking about socio-demographic characteristics, gestational age, and the number of children, a questionnaire to assess attitudes and behavioral changes, and Generalized anxiety disorder-7-item Scale. RESULTS: About 66.6% of pregnant women exhibited had mild anxiety levels, while 16.7% of them had moderate anxiety levels. Most pregnant women worried about their own, their children’s, unborn babies, and their elderly family members’ health, worked from home, avoided large-scale social activities and gatherings, and limited visits to health facilities. CONCLUSION: The COVID-19 pandemic increases the likelihood of anxiety symptoms and changes in attitudes and behaviors in pregnant women.

Introduction: Endometriosis is a severe disorder marked by endometrial tissue outside the uterus and linked to infertility, although typically manifesting as discomfort in the form of dysmenorrhea, dyspareunia, and pelvic pain. Dienogest is indicated as a first-line hormone treatment for endometriosis-related discomfort. The aim of this study is to analyze the efficacy of Dienogest on treating pelvic pain and dyspareunia compared to placebo or combined oral contraceptives (COC) in women with endometriosis. Methods: A systematic search is conducted in PubMed, ScienceDirect, and Google Scholar. The PRISMA 2020 rules were used to screen the articles that were obtained. For the review, studies that examined how using dienogest in improving endometriosis were exposed to were taken into consideration. In a meta-analysis utilizing a random-effects model, odds ratios with their 95% confidence intervals (CI) were provided. Results: Five studies that met the criteria for inclusion were determined to be pertinent to the association between using dienogest in improving endometriosis (n=711). The Dienogest group had substantially improve pelvic pain with a mean difference of 1.01 (95% CI 1.2, 0.82; p<0.00001) and dyspareunia with a mean difference of 0.58 (95% CI 1.09, 0.08; p=0.02) compared to placebo. Compared to combined oral contraceptives, COC had substantially improves dyspareunia with a mean difference of 0.99 (95% CI 0.62, 1.37; p<0.00001) and pelvic pain with a mean difference of 1.15 (95% CI 0.23, 0.83; p=0.01). Conclusion: Dienogest should be considered as an alternate treatment for endometriosis-related symptoms. In double-blind research, DNG efficacy was compared to placebo.

Introduction: The prevalence of endometriosis in women of reproductive age was still high. A previous study showed that the red fruit (Pandanus conoideus L.) extract consisted of alpha-tocopherol and beta carotene as antioxidants that could potentially be an alternative treatment in endometriosis. This study aimed to determine the effect of Red Fruit Extract Administration on the expression of TNF-α, microvessels density (MVD), and the area of endometriosis implant in endometriosis mice model. Methods: This was an experimental study with a randomized post-test control group design only applied to the endometriosis mice model and conducted in the Veterinary Faculty of Medicine Airlangga University, Surabaya. Twenty-eight endometriosis model mice were randomly divided into two groups. The control group (K) received CMC Na 5% for 14 days, and the treatment group (P) was given Red Fruit extract of 0,05 ml/day for 14 days. After day 28, mice were sacrificed, and immunohistochemical analysis was performed for TNF-α, microvessel density (MVD), and measured for endometriosis implant area. A T-test was used to analyze the comparison between groups. Results: Mean TNF-α, microvessel density, area of endometriosis implant in treatment group were 1,56±0,87, 1,26±0,48, 13,24±4,08, respectively. There was a statistically significant difference in TNF-α expression, MVD development, and area of endometriosis implant between the treatment and control groups (p<0.05). Conclusion: There was decreased expression of TNF-α, development of microvessel density, and area of endometriosis implant in endometriosis mice model given red fruit extract and proved to have potential effect as endometriosis therapy.

Introduction: The report of doctors who died with COVID-19 in Indonesia was high and influenced by several factors. This study examined COVID-19 infected doctors and mortality risk factors in East Java. Material and Methods: This observational cohort study was conducted among doctors infected with COVID-19 in East Java during March 2020-September 2021 and collected the COVID-19 infected doctors’ deaths report. Doctors received a questionnaire on the status of COVID-19, history of covid-19 infection, age, sex, type of doctor, type of specialization and resident, pregnancy, underlying disease and nutritional status. All data were described and potential risk factors’ association was analyzed. Results: We reported 2041 doctors infected with COVID-19. Majority of them (52,5%) was male, 162 doctors were more than 59 years old, 162 doctors (7,9%) were died and 41,4% was general practitioner. The odds ratio in each risk factor for mortality was older age doctors 15,468 (95% CI 10,587-22,601), male 6,128 (95% CI 3,906-9,614), general practitioner 2,461 (95% CI 1,769-3,423), doctors with underlying disease 39,842 (95% CI 23,077-68,798), Type II diabetes mellitus 82,504 (95% CI 42,767-159,162), cardiovascular disease 50,152 (95% CI 16,672-150,866), hypertension 19,425 (95% CI 10,528-35,840), Chronic Obstructive Pulmonary Disease 5,52 (95% CI 0,610-49,992), Asthma 2,091 (95% CI 0,626-6,986), Obesity 30.750 (95% CI 15,293-61,828) and Pregnant doctors 43.013 (95% CI 10.986-168.414) (p<0,05). Conclusion: Older age, male, general practitioner, doctors with underlying disease, cardiovascular disease, Type II diabetes mellitus, hypertension, chronic obstructive pulmonary disease, asthma, obesity, pregnant doctors had been mortality risk factors among COVID-19 infected doctors.